Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
AssigneeMaxim Pharmaceuticals, Inc.
InventorKurt R. Gehlsen
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for treating cell damage caused by reactive oxygen species in relation to a variety of skin disorders. More specifically, the present invention relates to the treatment skin disorders through the topical delivery of reactive oxygen metabolite production or release inhibiting compounds.
Claims24
A method for inhibiting and reducing enzymatically produced ROM-mediated oxidative damage to a subject's skin or mucosal membranes comprising topically delivering an effective dose of a compound that inhibits ROM production and release in a cosmetically acceptable carrier adapted for topical delivery to a subject suffering from said ROM-mediated oxidative damage.
A method for treating disorders of the skin or mucosa comprising topically delivering a cosmetically acceptable form of a compound selected from the group consisting of histamine, histamine dihydrochloride, histamine diphosphate, other histamine salts, esters, prodrugs, histamine receptor agonists, serotonin, 5HT agonists, NADPH oxidase inhibitor, and an endogenous histamine releasing compound.
A method for inhibiting the development of disorders of the skin or mucosa comprising the step of topically delivering an effective dose of a compound in a cosmetically acceptable carrier, wherein said compound is selected from the group consisting of histamine, histamine dihydrochloride, histamine diphosphate, other histamine salts, esters, prodrugs, histamine receptor agonists, serotonin, 5HT agonists, NADPH oxidase inhibitor, and an endogenous histamine releasing compound.
A method for treating disorders of the skin or mucosa resulting from cancer therapies comprising:
- a) identifying a patient receiving cancer treatment;
- and
- b) administering to said patient an effective dose of a compound in a cosmetically acceptable carrier, wherein said compound is selected from the group consisting of histamine, histamine dihydrochloride, histamine diphosphate, other histamine salts, esters, prodrugs, histamine receptor agonists, serotonin, 5HT agonists, NADPH oxidase inhibitor, and an endogenous histamine releasing compound.
Dependencies are inferred from the claim text.